Premium
A newly synthetic chromium complex – chromium(phenylalanine) 3 improves insulin responsiveness and reduces whole body glucose tolerance
Author(s) -
Yang Xiaoping,
Palanichamy Kamalakannan,
Ontko Allyn C.,
Rao M.N.A.,
Fang Cindy X.,
Ren Jun,
Sreejayan Nair
Publication year - 2005
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2005.01.049
Subject(s) - chromium , phenylalanine , insulin , medicine , chemistry , endocrinology , biochemistry , amino acid , organic chemistry
Low‐molecular‐weight organic chromium complexes such as chromium picolinate are often used as dietary supplements to improve insulin sensitivity and to correct dyslipidemia. However, toxicity associated with such chromium compounds has compromised their therapeutic value. The aim of this study was to evaluate the impact of a newly synthesized complex of chromium with phenylalanine, Cr(pa) 3 on insulin‐signaling and glucose tolerance. Cr(pa) 3 was synthesized by chelating chromium(III) with d ‐phenylalanine ligand in aqueous solution. In mouse 3T3‐adipocytes, Cr(pa) 3 augmented insulin‐stimulated glucose‐uptake as assessed by a radioactive‐glucose uptake assay. At the molecular level, Cr(pa) 3 enhanced insulin‐stimulated phosphorylation of Akt in a time‐ and concentration‐dependent manner without altering the phosphorylation of insulin receptor. Oral treatment with Cr(pa) 3 (150 μg/kg/d, for six weeks) in ob/ob (+/+) obese mice significantly alleviated glucose tolerance compared with untreated obese mice. Unlike chromium picolinate, Cr(pa) 3 does not cleave DNA under physiological reducing conditions. Collectively, these data suggest that Cr(pa) 3 may represent a novel, less‐toxic chromium supplement with potential therapeutic value to improve insulin sensitivity and glycemic control in type II diabetes.